{
  "abstract": "Addiction is a chronic relapsing condition characterized by compulsive reward seeking and impaired behavioral control, associated with major individual and societal burden. Mechanistic investigation in humans remains constrained by ethical limitations, uncontrolled exposure histories, and ecological confounds. Parkinson's disease treated with dopamine replacement therapy provides a human framework for investigating addiction‐relevant mechanisms under controlled dopaminergic modulation. We performed a narrative synthesis of clinical, neuropsychological, pharmacological, neuroimaging, and electrophysiological evidence linking impulse control disorders and dopamine dysregulation syndrome in Parkinson's disease to dimensional and circuit‐based models of addiction. We examined phenotypic and neurobiological convergences, experimental opportunities, and translational relevance while outlining its boundary conditions. A subset of Parkinson's disease patients exposed to dopamine replacement treatment develops impulse control disorders and dopamine dysregulation syndrome. Impulse control disorders comprise heterogeneous behavioral phenotypes that share selected dimensions with behavioral addictions, whereas dopamine dysregulation syndrome most closely approximates pharmacological substance use disorders. These phenotypes share selected addiction‐related dimensions, including craving, impaired control, compulsive reward‐seeking, and persistence despite harm, while showing partial clinical and neurobiological convergence with behavioral addictions and substance use disorders. Parkinson's disease patients with neuropsychiatric fluctuations may represent a sensitized vulnerability state in which dopaminergic modulation dynamically influences reward processing, motivation, and compulsive behaviors. Parkinson's disease under dopamine replacement therapy enables within‐subject dopaminergic manipulation, longitudinal observation, prospective assessment of vulnerability traits, multimodal neurobiological investigation, and reduced environmental confounding. It therefore provides a unique human window for investigating addiction‐relevant mechanisms under controlled dopaminergic modulation, complementing animal models while remaining constrained by disease‐specific boundary conditions.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurology Geneva University Hospital Geneva Switzerland",
    "Faculty of Medicine University of Geneva, Rue Michel‐Servet 1 Geneva Switzerland",
    "Rehabilitation Neural Engineering Laboratories University of Pittsburgh Pittsburgh Pennsylvania USA",
    "Physical Medicine and Rehabilitation University of Pittsburgh Pittsburgh Pennsylvania USA",
    "Bioengineering University of Pittsburgh Pittsburgh Pennsylvania USA",
    "Neuroscience of Emotion and Affective Lab University of Geneva Geneva Switzerland",
    "Addictology Division, Mental Health and Psychiatry Department Geneva University Hospital Geneva Switzerland",
    "Department of Basic Neurosciences, Faculty of Medicine University of Geneva Geneva Switzerland",
    "Synapsy Center for Mental Health Research University of Geneva Geneva Switzerland",
    "Department of Neurology Inselspital, University Hospital Bern, University of Bern Bern Switzerland"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Vanessa Fleury",
      "orcid": "0000-0001-5744-6829"
    },
    {
      "affs": [
        2,
        3,
        4
      ],
      "name": "Elvira Pirondini"
    },
    {
      "affs": [
        0,
        5
      ],
      "name": "Damien Benis"
    },
    {
      "affs": [
        0
      ],
      "name": "Tiffany Corbet"
    },
    {
      "affs": [
        6
      ],
      "name": "Gabriel Thorens"
    },
    {
      "affs": [
        0,
        1,
        7,
        8
      ],
      "name": "Christian Lüscher"
    },
    {
      "affs": [
        9
      ],
      "name": "Paul Krack"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a1xygmascfbx5.bib",
  "cited_by": 0,
  "doi": "10.1111/pcn.70118",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13732796/",
  "id": "a1xygmascfbx5",
  "issns": [
    "1323-1316",
    "1440-1819"
  ],
  "landing_url": "https://doi.org/10.1111/pcn.70118",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review Article"
    ],
    [
      "openalex",
      "2728|Parkinson's Disease Mechanisms and Treatments"
    ]
  ],
  "openalex": "W7202248019",
  "pdf_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/pcn.70118",
  "pmcid": "PMC13732796",
  "pmid": "42581657",
  "published": "2026-08-11",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/a1xygmascfbx5.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:22:42Z",
      "native_id": "PMC13732796",
      "source": "pmc",
      "url": "https://doi.org/10.1111/pcn.70118"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Parkinson's Disease Mechanisms and Treatments",
      "subfield": "neurology"
    }
  ],
  "title": "Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms",
  "title_text": "Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:22:42Z",
  "url": "https://research.draconitic.com/paper/a1xygmascfbx5",
  "venue": "Psychiatry and Clinical Neurosciences",
  "versions": []
}